USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PHARMACOGENETICS DIAGNOSTIC LABORATORIES
Address:
201 E. JEFFERSON STREET
Suite 309
LOUISVILLE, KY
Phone:
N/A
URL:
N/A
EIN:
134203042
DUNS:
135412190
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $115,534.00 1
SBIR Phase II $4,460,991.00 2

Award List:

Development of a Personalized Medicine Interface for the Safe and Effective Treat

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$115,534.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): PGXL Laboratories has access to a unique computational tool that can significantly reduce the morbidity and mortality associated with warfarin anticoagulation therapy. This project will yield a web-based software tool that will, for the first time, allow… More

Development of a Personalized Medicine Interface for the Safe and Effective Treat

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,394,314.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Warfarin is the most commonly used oral anticoagulant medication. Because an individual's proper warfarin dose is difficult to assess, most physicians initiate therapy at a standard dose and follow up with an INR blood test to ensure the medicine is working… More

Development of a Personalized Medicine Interface for the Safe and Effective Treat

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$3,066,677.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant):     Improvements in the safety and efficacy of warfarin therapy will result from intelligent application of knowledge derived from inherited characteristics (CYP2C9 and VKORC1) of individual patients, only when this knowledge is applied… More